The practical nurse (PN) is reinforcing information with a client who has been diagnosed with human immunodeficiency virus (HIV) about the antiretroviral medication regimen. Which client statement should the PN recognize as requiring an additional review of the information?

Choice A reason: Immune status is critical before administering the influenza vaccine, as immunocompromised individuals may have reduced vaccine efficacy or increased risk of adverse reactions. Conditions like HIV or chemotherapy weaken immune responses, requiring tailored vaccination strategies. Assessing immune status ensures the vaccine is safe and effective, guiding clinical decisions.

Choice B reason: While age influences vaccine type (e.g., high-dose for older adults), it is less critical than immune status for safety. Age is typically already known from records and does not directly affect immediate vaccine administration decisions. This choice is less relevant compared to immune status evaluation.

Choice C reason: Food allergies are generally irrelevant to influenza vaccines, which are not derived from food allergens. However, egg allergies may be considered for certain vaccines due to manufacturing processes, but this is distinct from food allergies broadly. This choice is incorrect as it lacks direct relevance.

Choice D reason: Gender does not impact influenza vaccine administration. Vaccine efficacy and safety are not significantly influenced by gender-specific physiological differences. This choice is incorrect, as it does not provide critical information needed to ensure the vaccine’s safety or effectiveness for the client.

Choice A reason: Less frequent urinary incontinence is a desired effect of oxybutynin, an antimuscarinic that relaxes bladder muscles, reducing involuntary contractions. This indicates therapeutic success in managing overactive bladder, not a concern requiring reporting, as it aligns with the drug’s intended action.

Choice B reason: Diminished urinary urgency is an expected outcome of oxybutynin, which inhibits bladder spasms by blocking acetylcholine receptors. This reduces the urge to urinate, improving overactive bladder symptoms, and does not warrant reporting, as it reflects the medication’s efficacy.

Choice C reason: Decreased urinary output is concerning, as oxybutynin’s anticholinergic effects may cause urinary retention by overly relaxing the bladder. This risks bladder distension or infection, requiring reporting to assess for obstruction or adjust dosing, making this the critical finding to address.

Choice D reason: Reduced urinary frequency is a therapeutic effect of oxybutynin, which decreases bladder contractions, allowing longer intervals between urination. This is a goal of overactive bladder treatment and does not require reporting, as it indicates the drug is working as intended.